Last updated: March 2026
Pinealon (EDR) is a synthetic tripeptide of 3 amino acids — glutamic acid, aspartic acid, and arginine — developed by Vladimir Khavinson's lab at the St. Petersburg Institute of Bioregulation. Unlike surface receptor binders, it enters the cell nucleus and directly interacts with DNA. Clinical studies cover TBI recovery, memory improvement, and neuroprotection under hypoxic conditions.
Pinealon (EDR) is a tripeptide consisting of glutamic acid, aspartic acid, and arginine. Like all Khavinson bioregulators, it doesn't bind surface receptors — it enters the cell nucleus and interacts directly with DNA.
Protects neurons under hypoxic (low oxygen) stress via activation of innate antioxidant systems. Reduces oxidative damage in brain tissue — relevant to TBI, stroke, and neurodegenerative conditions where hypoxia drives cell death.
Pinealon enters the cell nucleus, interacts with DNA promoter regions and histones — the same mechanism class as Epitalon. In Alzheimer's mouse model (PMC7795577), EDR regulated gene expression involved in AD pathogenesis.
Influences serotonin synthesis pathways in the brain. This modulation may explain the emotional balance improvements seen in the TBI clinical trial, as well as sleep architecture effects — Pinealon has been observed to improve REM and deep sleep duration.
Suppresses NMDA receptor-linked excitotoxicity — the process by which excessive glutamate signaling destroys neurons. This is directly relevant to TBI, ischemic stroke, and neurotoxicity conditions where glutamate flooding causes secondary brain damage.
Spanning the TBI clinical trial, Alzheimer's animal model, and preclinical mechanistic data.
Pinealon has actual human data — a clinical trial in 72 TBI patients using oral Pinealon + standard care vs standard care alone. This is more human evidence than most research peptides. That said, it's a single study from a Russian clinical program. Western RCT replication is still needed.
The most significant human data on Pinealon — 72 patients with traumatic brain injury treated with oral Pinealon plus standard therapy vs. standard therapy alone.
The most common Khavinson bioregulator combination — two pineal-origin peptides with complementary mechanisms.
The rationale: Epitalon targets pineal function and cellular longevity. Pinealon targets brain cortex cells and cognitive recovery. Used together in Khavinson's protocol — particularly for patients with cognitive decline or sleep-disrupted neurology. No human RCT data exists for this specific combination. The synergy is mechanistically plausible but not yet formally proven.
Doses used in research and Khavinson's clinical program. Not medical prescriptions — research context only.
Primary research behind the data on this page.
Honest assessment of where Pinealon research stands as of 2026.
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports MeetPeptide at no extra cost. All Swiss Chems products include third-party lab testing certificates.
Sleep optimization and cognitive support products relevant to Pinealon's research applications.
Affiliate links help support MeetPeptide at no extra cost to you.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and informational purposes only. It is not medical advice, and nothing here should be interpreted as a recommendation to use Pinealon or any peptide. Pinealon (EDR) is NOT approved by the FDA or EMA for human use. It is a research compound. Human data comes primarily from a Russian clinical program and has not been replicated in Western randomized controlled trials. The Alzheimer's mouse model data has not been validated in human trials. Always consult a qualified healthcare provider before making any health decisions. MeetPeptide does not sell peptides or endorse their use outside of legitimate research settings.